CLDX Celldex Therapeutics, Inc.
Q3 2025 10-Q
Filed: Nov 10, 2025Period ending Sep 30, 2025
Health Care
In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR Celldex Therapeutics, Inc. (CLDX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 10, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • No material changes to risk factors from 10-K dated February 27, 2025
- • New Employment Agreement for CCO Teri Lawver with $550K salary, 45% bonus target, severance up to 24 months’ pay post Change in Control
Quarterly Financial SummaryXBRL
Revenue
$0
▼ -100.0% YoY▼ -100.0% QoQ
Net Income
-$67M
▼ -59.2% YoY▲ +39.3% QoQ
ROE
-11.2%
Total Assets
$648M
EPS (Diluted)
$-1.01
▼ -57.8% YoY▼ -18.8% QoQ
Operating Cash Flow
-$49M
▲ +12.1% YoY▼ -10.5% QoQ
Source: XBRL data from Celldex Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Celldex Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.